Is NPCE Stock a Buy in 2026 After DIXI Exit and Margin Lift?

NeuroPace exits DIXI, doubles down on RNS as Q1 narrows losses and lifts 2026 guidance, Medicare and pricing actions support margins.
Open original source
NeuroPace exits DIXI, doubles down on RNS as Q1 narrows losses and lifts 2026 guidance, Medicare and pricing actions support margins.
Open original source